DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.
- Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.
- The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational products.
- Ratio Therapeutics will use the newly built GMP suites at the Eckert & Ziegler production site near Boston, MA, USA, from July 2022 for this purpose.
- As a radiopharmaceutical contract manufacturer, Eckert & Ziegler is able to produce small batches for Phase I, II and III clinical studies and large commercially applicable batch sizes.